Section I: Why evaluate?
The primary role ofthe clinical chemist is to ensure the provision of diagnostic laboratory services that provide optimal patient care and are as excellent as available technology and local economic factors will allow. However, an acceptable service is provided only if high standards of analytical performance are achieved and maintained. To monitor analytical performance, most laboratories use comprehensive internal and external quality control and assurance programmes. It should be realized, however, that the strategy of these schemes is to compare present performance with previous performance and not to provide data on whether the method itself is capable of fulfilling the analytical and clinical performance standards required.
Thus, before a method is brought into routine service in any laboratory, even the smallest, it is necessary to objectively assess the method itself, not only in terms of its analytical characteristics and ability to fulfill clinical needs, but also its impact on the laboratory, staff and budget. To obtain the data that allow a method to be so fully defined means that a proper and full evaluation must be carried out. It is preferable to do such an evaluation before a method (whether an instrument or reagent kit set) is purchased, but methods that are already purchased, even if in use for some time, should also be subjected to the same close scrutiny of evaluation. Once the evaluation has been made, the method is fully characterized. The data generated can then be retained in the laboratory; only then can quality control and assurance programmes be instituted and used to ensure that the well-defined and acceptable analytical performance of the method is being maintained.
The total evaluation process should be a logical progression through the steps of pre-purchase or pre-service assessment, familiarization, evaluation and objective assessment of acceptability. None of these steps should be omitted before a candidate method is brought into routine service.
Many evaluation protocols have been published in the literature of clinical chemistry. Most of these are well thought-122 out and carefully written. They tend, however, to be written for the expert and are consequently somewhat theoretical. A brief.
working guide for the clinical chemistry 'layman' has until now been lacking. This publication provides such a practical guide--a route-map for the driver who has either never been on this road before or is not very familiar with the terrain.
The 'Evaluation Kit' is simple to use. Section II contains the terms and phrases used in evaluation theory and practice; this may be omitted by those familiar with field. Sections III to IX provide the detailed route-map, starting with the itinerary, and then progressing in a logical manner through the stages of the evaluation process.
This material is based on practical experience, on theory, on previously published work and on current national and international recommendations. Major sources of information are acknowledged in the Bibliography (Section X).
Section II: Terminology
Many of the definitions of the terms and phrases used in clinical chemistry are yet to be agreed upon universally. In this publication, the definitions promulgated by the International Federation of Clinical Chemistry are generally used.
A method which after exhaustive investigation has been shown to have no known source of inaccuracy or ambiguity. The smallest single result which, with a stated probability, can be distinguished from a true blank. Difference between an estimate of a quantity and its true value. Procedure of utilizing, for quality control purposes, the results of several laboratories which analyse the same specimens. Standard (2) To identify the candidate method that is most likely to fulfill the total specification. The assessment of the candidates should be made using the detailed check-list in figure 2.
Notes on the check-list (figure 2) (9) Between-day imprecision (SD or CV).
Sales literature normally provides some basic performance data, usually both between-day and within- 
Present method: Step (g) to give ,X T" X C .,X T" X C Figure 4 (a). (1) Add all the results in column A.
(2) Divide this total by the number of analyses (n) to give the mean value (2).
(3) Use column B to list values of result-mean (x-2). (4) Use column C to list values of (result-means) 2 (x-2)2. (5) Add the values in column C to obtain E(x-x)2, divide this by the number of analyses-1 (n-1), and take the square root of this number to obtain the standard deviation.
(6) Divide the standard deviation by the mean to obtain the coefficient of variation.
Record the results of statistical analyses. 0, 0"2, 0"4, 0"6, 0-8 and 1"0 ml (or multiples thereof). To one set of tubes add:
1.0, 0"8, 0"6, 0.4, 0.2 and 0ml (or appropriate multiples) of distilled water, physiological saline or appropriate diluent, for example hormone-depleted serum for immunoassay techniques. To the other set of tubes, add:
1.0, 0-8, 0-6, 0.4, 0.2 and 0ml (or appropriate multiples) of a specimen from a patient which has a low level of analyte.
Note the volumes Used as shown in figure 4 (f).
Analyse both sets of samples in duplicate and insert the results as indicated in figure 4 (f) Figure 4 (e).
G. H. White and figure 6 to help decision-making. Criteria for acceptance or rejection of the method are as follows.
(1) Within-run imprecision After outliers have been rejected on objective grounds, the within-run imprecision of the method can be accepted as satisfactory if the SD is equal to or less than half of the intraindividual biological variation of the analyte (the ideal), or
